The U.S. pharmaceutical supply chain has become increasingly complex and globally dependent over the past few decades. Various regulatory and economic factors have led to the offshoring of pharmaceutical manufacturing for many essential medications. Consolidation of manufacturing activities in a small number of countries has been theorized to be a potential cause of increasing drug shortages and, more recently, a matter of national security. This presentation will give a broad overview of U.S. pharmaceutical supply chain dynamics, increasing public interest in this topic, and some ongoing efforts to increase resiliency. By presenting a high-level overview of the Defense Logistics Agency Customer Pharmacy Operations Center’s support to both Department of Defense and whole of federal government COVID-19 response, the audience should gain an understanding of key logistical challenges in today’s pharmaceutical market and opportunities for future improvement.
Describe the global nature of the pharmaceutical supply chain.
Identify external factors that influence pharmaceutical manufacturing trends.
Discuss examples of current federal government initiatives to increase pharmaceutical supply chain resiliency.
Analyze DoD response to COVID-19 pharmaceutical supply chain interruptions and identify opportunities for future improvement.